Meta Navigation

Header Image

Geistlich Pharma has won second prize in the “Business Transformation” category of the “SAP Quality Excellence Awards”.

Corporate News

2014 · 2013 ·
  • It is with deep sadness that we say farewell to a unique person, pioneering entrepreneur and visionary.

    Peter Geistlich

    Dr. Ing. chem. ETH

    *8 May 1927            †23 July 2014

    For over 60 years, Dr. Peter Geistlich creatively and tirelessly broke constant new ground in our company. He initially ran our industrial activities in Wolhusen with his entrepreneurial spirit.

    In the 1980's he initiated our entry into medical technology with...

  • The new website of Geistlich Pharma AG has been live since today. With the re-launch, the information content has been tailored even more specifically to the information requirements of specialist clinic personnel and their patients. In addition to product information, therapy concepts with case studies and easy-to-understand video material are also available. Furthermore, the website has a fresher design and a more user-friendly web architecture.

  • In 2013, the global economy was once again characterised by uncertainty and reticence. In this difficult environment, Geistlich Pharma AG again asserted itself very well as a Swiss SME. The company posted solid growth and strengthened or even expanded its position in virtually all its markets. Once again, the balanced geographical mix, an attractive product pipeline and the operational strength of the company were contributing factors.

  • Innovation is an everyday occurrence at Geistlich. The film “The Art of Innovation” is designed to give a better idea of what this everyday life looks like and to make it accessible to the public at large.

  • Following on from the bone replacement material Geistlich Bio-Oss®, the Japanese authorities have now also granted a licence to Geistlich Bio-Gide®. The sales launch of the collagen membrane for bone regeneration is to take place shortly.

  • With immediate effect two new laws in the US and France will regulate collaboration between medicine and industry. The goal of both laws is to ensure greater transparency in future towards the general public and thus prevent conflicts of interest. All payments from manufacturers to the medical profession will be published on the Internet.

  • In October 2013, Dr Peter Geistlich, the President of the Board of Directors of Geistlich Pharma AG, together with Geistlich Pharma AG in the USA, launched the Osteo Science Foundation which has its registered office in Philadelphia. The goal of the Foundation is to support and promote independent research in North America in oral and maxillofacial surgery and to put its results from theory into practice.

  • In September, the 3rd Central Switzerland Economic Forum was held on the Pilatus on the topic of "Education – Innovation – Workforce". Paul Note, CEO of Geistlich Pharma AG, was the podium guest at the workshop "Innovation and knowledge transfer". With renowned representatives from business and education, he discussed the topic: What promotes innovations and drives the transfer of knowledge; where are the obstacles?

     

  • Researchers of the University of Zurich has presented new results from a long-term study over 12 to 14 years. The study shows that implants placed simultaneously with guided bone regeneration (GBR) have a high survival rate not significantly different to implants placed in ample vital bone.

  • The Osteology Foundation is celebrating its 10th anniversary at the International Symposium in Monaco. Geistlich Pharma, together with Dr. Peter Geistlich, set up the Foundation in 2003 in order to promote research in regenerative dentistry and make it available to practitioners. Co-operations between research, hospitals and industry have since made possible better treatment methods for the patients.

PRESS CONTACT
Dr. Mirjam Kessler
Director Corporate Communications
Flickr
Flickr Photo Stream

For printable images, please send an e-mail to mediageistlich.ch

YouTube
YouTube Geistlich Channel

Geistlich Pharma AG - Channel­